Local Scientific Organizer
Prof. Alessandro Padovani
School of Neurology, University of Brescia
Scientific and Organizing Committee
University of Brescia (Italy)
Via del Rastrello, 7 – 53100 Siena
Tel. 0577 286003 email: email@example.com
CME - Continuing Medical Education (for italian participants)
The conference Provider is SIN. (Italian Society of Neurology cod. no. 1802).
Event ID: 1802-297988
Assigned Credits: 31,5
Application has been made for the awarding of accreditation to the Italian National Commission for Continuing Education in Medicine (ECM) of AGENAS (the Italian National Agency for Regional Health Services) for Italian partecipants and also for the European Agency for international delegates.
The course will be accredited for the following Professions:
- Medical Doctor (Neurology, Geriatrics, Psychiatry, Psychotherapy)
- Physical Therapist
EACCME Acrreditation (for UEMS participants)
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 20 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Accreditation Letter Information
The Summer School “Biological and Clinical converging pathways in Alzheimer and Parkinson disease” is an opportunity for young neurologists who are interested in specializing in Neurodegenerative diseases to receive in-depth instruction from internationally-recognized experts. Students will attend large lectures and panel discussions with question and answer sessions and will have the opportunity to discuss clinical cases of atypical dementia and movement disorders and engage in a differential diagnosis with the international experts.
Understand the common and divergent pathways across neurodegenerative diseases
• Propose a differential diagnosis for complex cases and propose specific clinical/imaging/neurophysiological or biological markers assessment
• Propose a symptomatic personalized treatment for dementia and movement disorder
• Understand the rationale and review the more recent evidences for new disease-modifying target therapies across neurodegenerative diseases
Expiration date: September 3rd 2020